Effects of 5-aza-2'-deoxycytidine and interferon-alpha on differentiation and oncogene expression in HL-60 myeloid leukemic cells
- PMID: 1381972
- DOI: 10.1097/00001813-199206000-00012
Effects of 5-aza-2'-deoxycytidine and interferon-alpha on differentiation and oncogene expression in HL-60 myeloid leukemic cells
Abstract
The antineoplastic effects of 5-aza-2'-deoxycytidine (5-AZA-CdR) and interferon-alpha (IFN-alpha) on human HL-60 myeloid leukemic cells were investigated. 5-AZA-CdR and IFN-alpha in combination produced a greater inhibition of DNA synthesis and cell growth than either agent alone. The co-treatment produced a synergistic reduction in the clonogenicity of the HL-60 leukemic cells. In addition, this combination also produced a greater reduction in mRNA expression for c-myc than each agent alone. This antileukemic action produced by 5-AZA-CdR and IFN-alpha in combination correlated with the increase in induction of differentiation of the HL-60 leukemic cells. These results suggest that 5-AZA-CdR and IFN-alpha in combination produces an enhancement of their antineoplastic action on HL-60 human myeloid leukemic cells.
Similar articles
-
Induction of cytidine deaminase in HL-60 myeloid leukemic cells by 5-aza-2'-deoxycytidine.Leuk Res. 1990;14(9):751-4. doi: 10.1016/0145-2126(90)90067-j. Leuk Res. 1990. PMID: 1700230
-
Effect of 5-aza-2'-deoxycytidine and retinoic acid on differentiation and c-myc expression in HL-60 myeloid leukemic cells.Cancer Lett. 1990 Oct 8;54(1-2):21-8. doi: 10.1016/0304-3835(90)90086-d. Cancer Lett. 1990. PMID: 1698532
-
Interaction of 5-aza-2'-deoxycytidine with amsacrine or 1,25-dihydroxyvitamin D3 on HL-60 myeloid leukemic cells and inhibitors of cytidine deaminase.Leukemia. 1993 May;7 Suppl 1:17-20. Leukemia. 1993. PMID: 7683351
-
Pharmacological approach for optimization of the dose schedule of 5-Aza-2'-deoxycytidine (Decitabine) for the therapy of leukemia.Leukemia. 1997 Feb;11(2):175-80. doi: 10.1038/sj.leu.2400550. Leukemia. 1997. PMID: 9009076 Review.
-
Pharmacological approach for optimization of the dose schedule of 5-Aza-2'-deoxycytidine (Decitabine) for the therapy of leukemia.Leukemia. 1997 Mar;11 Suppl 1:S1-6. Leukemia. 1997. PMID: 9130684 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources